8.77 USD
▲+0.17+2.57%
盘后 8.52 -0.35%
2026-08-03
市值
$79.02M
市盈率
—
EPS
-0.71
股息率
—
52 周区间
3.92 – 19.15
成交量
42.28K
Beta
0.09
目标价
13.67
52W 低 3.9252W 高 19.15
价格走势
公司简介
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. T...